Last reviewed · How we verify
Novosis(bongros/BMP-2) — Competitive Intelligence Brief
phase 3
Recombinant protein growth factor
BMP-2 receptor (ALK2/ALK3)
Orthopedics / Bone regeneration
Small molecule
Live · refreshed every 30 min
Target snapshot
Novosis(bongros/BMP-2) (Novosis(bongros/BMP-2)) — Daewoong Pharmaceutical Co. LTD.. Novosis is a recombinant human bone morphogenetic protein-2 (BMP-2) that promotes bone formation by stimulating osteoblast differentiation and new bone growth.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Novosis(bongros/BMP-2) TARGET | Novosis(bongros/BMP-2) | Daewoong Pharmaceutical Co. LTD. | phase 3 | Recombinant protein growth factor | BMP-2 receptor (ALK2/ALK3) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Recombinant protein growth factor class)
- Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Novosis(bongros/BMP-2) CI watch — RSS
- Novosis(bongros/BMP-2) CI watch — Atom
- Novosis(bongros/BMP-2) CI watch — JSON
- Novosis(bongros/BMP-2) alone — RSS
- Whole Recombinant protein growth factor class — RSS
Cite this brief
Drug Landscape (2026). Novosis(bongros/BMP-2) — Competitive Intelligence Brief. https://druglandscape.com/ci/novosis-bongros-bmp-2. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab